Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)
NCT01486771
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
1. Eligible eyes will have active PDR with high risk characteristics (HRC) as defined by the DRS. All eyes must meet at least one or both of the following criteria:
- Mild neovascularization of the disc (NVD) of at least 1/4 to 1/3 disc area as shown in standard photograph 10A of the DRS.
- Moderate neovascularization of the retina elsewhere (NVE) of at least 1/2 disc area as shown in standard photograph 7 of the DRS.
2. ETDRS visual acuity score greater than or equal to 24 letters (approximately 20/320) and less than or equal to 85 letters (approximately 20/20) by the ETDRS visual acuity protocol at the screening visit.
3. Eyes with mild pre-retinal hemorrhage (PRH) or mild vitreous hemorrhage (VH) that does not interfere with clear visualization of the macula and optic disc are eligible for this study.
4. Evaluating physician believes that PRP can be safely withheld for 3 weeks.
1. Presence of moderate or dense PRH or VH that prevents clear visualization of the
macula and/or optic disc.
2. Presence of either:
- significant epiretinal membranes involving the macula, OR
- proliferative diabetic membranes along the major retinal arcades that are
extensive enough to cause either:
- significant vitreomacular traction, OR
- significant impairment in visual acuity.
3. Presence of any tractional retinal detachment.
4. Severe ischemia involving the foveal avascular zone as determined by fluorescein
angiography performed at the initial screening visit.
5. Significant media opacity (due to cornea, anterior chamber, or lens) precluding clear
visualization of the macula or optic disc.
6. Presence of neovascular glaucoma with or without hyphema.
7. Previous treatment with intravitreal steroid injections in the study eye within 6
months of baseline.
8. Previous treatment with peribulbar steroid injections in the study eye within 90 days
of baseline
9. Previous PRP laser treatment in the study eye within 90 days of baseline visit.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- McAllen, Texas
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED) | |||
Official Title ICMJE | A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase | |||
Brief Summary | Intravitreal injections of pegaptanib will induce the regression of Proliferative Diabetic Retinopathy (PDR) and reduce the need for retinal photocoagulation. | |||
Detailed Description | Primary Objective: To further establish the efficacy of intravitreal pegaptanib injections in the regression of retinal neovascularization secondary to high-risk PDR, as compared to standard panretinal photocoagulation (PRP) Secondary Objective: To maintain the regression of PDR after the induction phase with intravitreal pegaptanib injections administered at 12-week intervals, as compared to standard PRP To maintain the regression of PDR after the induction phase with retinal photocoagulation applied to areas of ischemia (Selective Laser Photocoagulation), as compared to standard PRP To evaluate the rate of recurrence of neovascularization after 6 intravitreal pegaptanib injections To determine if intravitreal pegaptanib will reduce the area and/or volume of concomitant diabetic macular edema, as assessed by leakage on fluorescein angiography (FA) and/or optical coherence tomography (OCT) To determine if intravitreal pegaptanib injections maintain or reduce the loss of best-corrected visual acuity | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 4 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Factorial Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Proliferative Diabetic Retinopathy | |||
Intervention ICMJE | Drug: Macugen ® (pegaptanib sodium)
Patients assigned to either IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. The group will then receive an intravitreal injection every 12 weeks. Patients assigned to IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. After the third injection subjects in this group will receive Selective Laser Photocoagulation at Week 18. Patients assigned to Panretinal Photocoagulation will act as the control group. Subjects in this group will receive standard Panretinal Photocoagulation using a modified ETDRS protocol. All intravitreal study injections will consist of 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection. | |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Unknown status | |||
Actual Enrollment ICMJE | 30 | |||
Original Actual Enrollment ICMJE | Same as current | |||
Estimated Study Completion Date ICMJE | February 2014 | |||
Estimated Primary Completion Date | August 2013 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT01486771 | |||
Other Study ID Numbers ICMJE | MPDRS-ED | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Victor H. Gonzalez, MD, Valley Retina Institute | |||
Study Sponsor ICMJE | Valley Retina Institute | |||
Collaborators ICMJE | Pfizer | |||
Investigators ICMJE |
| |||
PRS Account | Valley Retina Institute | |||
Verification Date | December 2011 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |